Anatomical distribution of nucleoside system in the human brain and implications for therapy

Adenosine: A Key Link between Metabolism and Brain Activity

Volumn , Issue , 2013, Pages 621-656

  Kovács, Zsolt ^a   Dobolyi, Arpád ^b  

^a UNIVERSITY OF WEST HUNGARY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Anatomical distribution of nucleoside system; Human brain diseases and therapy; Nucleosides

Indexed keywords

EID: 84879399892     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-3903-5_29     Document Type: Chapter

References (251)

1. Agnati LF, Fuxe K, Ruggeri M, Merlo Pich E, Benfenati F, Volterra V, Ungerstedt U, Zini I (1989) Effects of chronic treatment with uridine on striatal dopamine release and dopamine related behaviours in the absence or the presence of chronic treatment with haloperidol. Neurochem Int 15:107-113
2. Akhondzadeh S, Shasavand E, Jamilian H, Shabestari O, Kamalipour A (2000) Dipyridamole in the treatment of schizophrenia: Adenosine-dopamine receptor interactions. J Clin Pharm Ther 25:131-137
3. Akhondzadeh S, Safarcherati A, Amini H (2005) Bene fi cial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: A double blind, randomized and placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 29:253-259
4. Akhondzadeh S, Milajerdi MR, Amini H, Tehrani-Doost M (2006) Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: A double-blind, randomized, placebo-controlled trial. Bipolar Disord 8:485-489
5. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK (2005) Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain 9:463-484
6. Arias-Menendez L (2002) Targeting HIV: Antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci 23:381-388
7. Baldo BA, Koob GF, Markou A (1999) Role of adenosine A2 receptors in brain stimulation reward under baseline conditions and during cocaine withdrawal in rats. J Neurosci 19:11017-11026
8. Baldwin SA, Mackey JR, Cass CE, Young JD (1999) Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today 5:216-224
9. Baldwin SA, Yao SYM, Hyde RJ, Ng AML, Foppolo S, Barnes K, Ritzel MWL, Cass CE, Young JD (2005) Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem 280:15880-15887
10. Barnes K, Dobrzynski H, Foppolo S, Beal PR, Ismat F, Scullion ER, Sun L, Tellez J, Ritzel MW, Claycomb WC, Cass CE, Young JD, Billeter-Clark R, Boyett MR, Baldwin SA (2006) Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ Res 99:510-519
11. Barraco RA, Swanson TH, Phillis JW, Berman RF (1984) Anticonvulsant effects of adenosine analogues on amygdaloid-kindled seizures in rats. Neurosci Lett 46:317-322
12. Barrett RJ, Lamson MJ, Johnson J, Smith WB (2005) Pharmacokinetics and safety of binodenoson after intravenous dose escalation in healthy volunteers. J Nucl Cardiol 12:166-171
13. Bastia E, Xu YH, Scibelli AC, Day YJ, Linden J, Chen JF, Schwarzschild MA (2005) A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. Neuropsychopharmacology 30:891-900
14. Bender E, Buist A, Jurzak M, Langlois X, Baggerman G, Verhasselt P, Ercken M, Guo HQ, Wintmolders C, Van den Wyngaert I, Van Oers I, Schoofs L, Luyten W (2002) Characterization of an orphan G protein-coupled receptor localized in the dorsal root ganglia reveals adenine as a signaling molecule. Proc Natl Acad Sci USA 99:8573-8578
15. Benesch M, Urban C (2008) Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin Pharmacother 9:301-309
16. Berne RM, Rubio R, Curnish RR (1974) Release of adenosine from ischemic brain: effect on cerebral vascular resistance and incorporation into cerebral adenine nucleotides. Circ Res 35:262-271
17. Bertram EH (2009) Temporal lobe epilepsy: where do the seizures really begin? Epilepsy Behav 14(Suppl 1):32-37
18. Beukers MW, Chang LC, von Frijtag Drabbe Kunzel JK, Mulder-Krieger T, Spanjersberg RF, Brussee J, Ijzerman AP (2004) New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity pro fi le compared to the reference agonist N-ethylcarboxamidoadenosine. J Med Chem 47:3707-3709
19. Bjerring PN, Hauerberg J, Jørgensen L, Frederiksen HJ, Tofteng F, Hansen BA, Larsen FS (2010) Brain hypoxanthine concentration correlates to lactate/pyruvate ratio but not intracranial pressure in patients with acute liver failure. J Hepatol 53:1054-1058
20. Blum D, Hourez R, Galas MC, Popoli P, Schiffmann SN (2003) Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. Lancet Neurol 2:366-374
21. Boison D (2005) Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies. Neuroscientist 11:25-36
22. Boison D (2008) The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol 84:249-262
23. Boison D (2011) Modulators of nucleoside metabolism in the therapy of brain diseases. Curr Top Med Chem 11:1068-1086
24. Boison D, Singer P, Shen HY, Feldon J, Yee BK (2012) Adenosine hypothesis of schizophrenia-Opportunities for pharmacotherapy. Neuropharmacology 62:1527-1543
25. Borbely AA, Tobler I (1989) Endogenous sleep-promoting substances and sleep regulation. Physiol Rev 69:605-670
26. Borrmann T, Abdelrahman A, Volpini R, Lambertucci C, Alksnis E, Gorzalka S, Knospe M, Schiedel AC, Cristalli G, Müller CE (2009) Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family. J Med Chem 52:5974-5989
27. Bowley MP, Drevets WC, Öngür D, Price JL (2002) Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 52:404-412
28. Brauch RA, Adnan El-Masri M, Parker JC Jr, El-Mallakh RS (2006) Glial cell number and neuron/glial cell ratios in postmortem brains of bipolar individuals. J Affect Disord 91:87-90
29. Breckenridge A (2005) Pharmacology of drugs for HIV. Medicine 33:30-31
30. Brundege JM, Williams JT (2002) Increase in adenosine sensitivity in the nucleus accumbens following chronic morphine treatment. J Neurophysiol 87:1369-1375
31. Burnstock G, Fredholm BB, Verkhratsky A (2011) Adenosine and ATP receptors in the brain. Curr Top Med Chem 11:973-1011
32. Bzowska A, Kulikowska E, Shugar D (2000) Purine nucleoside phosphorylases: properties, functions, and clinical aspects. Pharmacol Therapeut 88:349-425
33. Cansev M (2006) Uridine and cytidine in the brain: Their transport and utilization. Brain Res Rev 52:389-397
34. Cansev M, Ulus IH, Wang L, Maher TJ, Wurtman RJ (2008) Restorative effects of uridine plus docosahexaenoic acid in a rat model of Parkinson's disease. Neurosci Res 62:206-209
35. Castane A, Soria G, Ledent C, Maldonado R, Valverde O (2006) Attenuation of nicotine-induced rewarding effects in A2A knockout mice. Neuropharmacology 51:631-640
36. Ceballos G, Tuttle JB, Rubio R (1994) Differential distribution of purine metabolizing enzymes between glia and neurons. J Neurochem 62:1144-1153
37. Ceruti S, Franceschi C, Barbieri D, Malorni W, Camurri A, Giammarioli AM, Ambrosini A, Racagni G, Cattabeni F, Abbracchio MP (2000) Apoptosis induced by 2-chloro-adenosine and 2-chloro-2'-deoxy-adenosine in a human astrocytoma cell line: differential mechanisms and possible clinical relevance. J Neurosci Res 60:388-400
38. Chang R, Algird A, Bau C, Rathbone MP, Jiang S (2008) Neuroprotective effects of guanosine on stroke models in vitro and in vivo. Neurosci Lett 431:101-105
39. Chen TH, Wang MF, Liang YF, Komatsu T, Chan YC, Chung SY, Yamamoto S (2000) A nucleoside-nucleotide mixture may reduce memory deterioration in old senescence-accelerated mice. J Nutr 130:3085-3089
40. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N Jr, Schwarzschild MA (2001) Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21:RC143
41. Chou SY, Lee YC, Chen HM, Chiang MC, Lai HL, Chang HH, Wu YC, Sun CN, Chien CL, Lin YS, Wang SC, Tung YY, Chang C, Chern Y (2005) CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J Neurochem 93:310-320
42. Ciccarelli R, Ballerini P, Sabatino G, Rathbone MP, D'Onofrio M, Caciagli F, Di Iorio P (2001) Involvement of astrocytes in purine-mediated reparative processes in the brain. Int J Dev Neurosci 19:395-414
43. Connolly GP, Duley JA (1999) Uridine and its nucleotides: biological actions, therapeutic potentials. Trends Pharmacol Sci 20:218-225
44. Corn fi eld LJ, Hu S, Hurt SD, Sills MA (1992) [3 H]2-phenylaminoadenosine ([3 H]CV 1808) labels a novel adenosine receptor in rat brain. J Pharmacol Exp Ther 263:552-561
45. Cunha RA (2005) Neuroprotection by adenosine in the brain: from A(1) receptor activation to A (2A) receptor blockade. Purinergic Signal 1:111-134
46. Cunha RA, Johansson B, Fredholm BB, Ribeiro JA, Sebastiao AM (1995) Adenosine A2A receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus. Neurosci Lett 196:41-44
47. Curros-Criado MM, Herrero JF (2005) The antinociceptive effects of the systemic adenosine A1 receptor agonist CPA in the absence and in the presence of spinal cord sensitization. Pharmacol Biochem Behav 82:721-726
48. D'Alimonte I, D'Auro M, Citraro R, Biagioni F, Jiang S, Nargi E, Buccella S, Di Iorio P, Giuliani P, Ballerini P, Caciagli F, Russo E, De Sarro G, Ciccarelli R (2009) Altered distribution and function of A2A adenosine receptors in the brain of WAG/Rij rats with genetic absence epilepsy, before and after appearance of the disease. Eur J Neurosci 30:1023-1035
49. Dall'Igna OP, Porciúncula LO, Souza DO, Cunha RA, Lara DR (2003) Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 138:1207-1209
50. Dall'Igna OP, Fett P, Gomes MW, Souza DO, Cunha RA, Lara DR (2007) Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive de fi cits in mice. Exp Neurol 203:241-245
51. Datta S, Maclean RR (2007) Neurobiological mechanisms for the regulation of mammalian sleepwake behavior: reinterpretation of historical evidence and inclusion of contemporary cellular and molecular evidence. Neurosci Biobehav Rev 31:775-824
52. Dawson DM (1971) Absence of guanine deaminase from cerebellum. Neurology 21:621-626
53. De Clercq E (2004) Antiviral drugs in current clinical use. J Clin Virol 30:115-133
54. De Clercq E (2009) Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33:307-320
55. De Clercq E (2011) A 40-year journey in search of selective antiviral chemotherapy. Annu Rev Pharmacol Toxicol 51:1-24
56. De Mattia E, Toffoli G (2009) C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fl uoropyrimidine-based therapy personalisation. Eur J Cancer 45:1333-1351
57. De Mendonca A, Sebastiao AM, Ribeiro JA (1995) Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A1 receptor activation. Neuroreport 6:1097-1100
58. De Oliveira DL, Horn JF, Rodrigues JM, Frizzo ME, Moriguchi E, Souza DO, Wofchuk S (2004) Quinolinic acid promotes seizures and decreases glutamate uptake in young rats: reversal by orally administered guanosine. Brain Res 1018:48-54
59. Deckert J, Abel F, Kunig G, Hartmann J, Senitz D, Maier H, Ransmayr G, Riederer P (1998) Loss of human hippocampal adenosine A 1 receptors in dementia: evidence for lack of speci fi city. Neurosci Lett 244:1-4
60. Deutsch SI, Long KD, Rosse RB, Mastropaolo J, Eller J (2005) Hypothesized de fi ciency of guanine-based purines may contribute to abnormalities of neurodevelopment, neuromodulation, and neurotransmission in Lesch-Nyhan syndrome. Clin Neuropharmacol 28:28-37
61. Di Iorio P, Ballerini P, Traversa U, Nicoletti F, D'Alimonte I, Kleywegt S, Werstiuk ES, Rathbone MP, Caciagli F, Ciccarelli R (2004) The antiapoptotic effect of guanosine is mediated by the activation of the PI 3-kinase/AKT/PKB pathway in cultured rat astrocytes. Glia 46:356-368
62. Dietrich WD (1998) Neurobiology of stroke. Int Rev Neurobiol 42:55-101
63. Dobolyi A, Szikra T, Kekesi AK, Kovacs Z, Juhasz G (1999) Uridine is released by depolarization and inhibits unit activity in the rat hippocampus. Neuroreport 10:3049-3053
64. Dobolyi A, Reichart A, Szikra T, Nyitrai G, Kekesi KA, Juhasz G (2000) Sustained depolarisation induces changes in the extracellular concentrations of purine and pyrimidine nucleosides in the rat thalamus. Neurochem Int 37:71-79
65. Dobolyi A, Juhasz G, Kovacs Z, Kardos J (2011) Uridine function in the central nervous system. Curr Top Med Chem 11:1058-1067
66. Durieux PF, Schiffmann SN, de Kerchove d'Exaerde A (2011) Targeting neuronal populations of the striatum. Front Neuroanat 5:40
67. Dwivedi C, Harbison RD (1975) Anticonvulsant activities of delta-8 and delta-9 tetrahydrocannabinol and uridine. Toxicol Appl Pharmacol 31:452-458
68. Eells JT, Spector R (1983) Purine and pyrimidine base and nucleoside concentrations in human cerebrospinal fl uid and plasma. Neurochem Res 8:1451-1457
69. Ekonomou A, Angelatou F, Vergnes M, Kostopoulos G (1998) Lower density of A1 adenosine receptors in nucleus reticularis thalami in rats with genetic absence epilepsy. Neuroreport 9:2135-2140
70. Elzein E, Zablocki J (2008) A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs 17:1901-1910
71. Erion MD, Ugarkar BG, Dare J, Castellino AJ, Fujitaki JM, Dixon R, Appleman JR, Wiesner JB (1997) Design, synthesis and anticonvulsant activity of the potent adenosine kinase inhibitor GP3269. Nucleos Nucleot 16:1013-1021
72. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M (2009) Midlife coffee and tea drinking and the risk of late-life dementia: A population-based CAIDE study. J Alzheimers Dis 16:85-91
73. Farabegoli C, Merlo Pich E, Cimino M, Agnati LF, Fuxe K (1988) Chronic uridine treatment reduces the level of [3 H]spiperone-labelled dopamine receptors and enhances their turnover rate in striatum of young rats: relationship to dopamine-dependent behaviours. Acta Physiol Scand 132:209-216
74. Fastbom J, Pazos A, Probst A, Palacios JM (1986) Adenosine A1 receptors is human brain: characterisation and autoradiographic visualization. Neurosci Lett 65:127-132
75. Fastbom J, Pazos A, Palacios JM (1987) The distribution of adenosine A1 receptors and 5'-nucleotidase is the brain of some commonly used experimental animals. Neuroscience 22:813-826
76. Fava M (2003) The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. J Clin Psychiatry 64(Suppl 13):26-29
77. Fedele DE, Li T, Lan JQ, Fredholm BB, Boison D (2006) Adenosine A1 receptors are crucial in keeping an epileptic focus localized. Exp Neurol 200:184-190
78. Fernández JR, Sweet ES, Welsh WJ, Firestein BL (2010) Identi fi cation of small molecule compounds with higher binding af fi nity to guanine deaminase (cypin) than guanine. Bioorg Med Chem 18:6748-6755
79. Ferré S, Fredholm BB, Morelli M, Popoli P, Fuxe K (1997) Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia. Trends Neurosci 20:482-487
80. Ferré S, Diamond I, Goldberg SR, Yao L, Hourani SM, Huang ZL, Urade Y, Kitchen I (2007) Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain. Prog Neurobiol 83:332-347
81. Fields RD, Burnstock G (2006) Purinergic signalling in neuron-glia interactions. Nat Rev Neurosci 7:423-436
82. Firestein BL, Brenman JE, Aoki C, Sanchez-Perez AM, El-Husseini AE, Bredt DS (1999) Cypin: A cytosolic regulator of PSD-95 postsynaptic targeting. Neuron 24:659-672
83. Franklin A, Blanden RV (2007) Potential inhibition of somatic hypermutation by nucleoside analogues. Mol Immunol 44:666-669
84. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51:83-133
85. Fredholm BB, Ijzerman AP, Jacobson KA, Klotz KN, Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classi fi cation of adenosine receptors. Pharmacol Rev 53:527-552
86. Frizzo ME, Lara DR, Prokopiuk Ade S, Vargas CR, Salbego CG, Wajner M, Souza DO (2002) Guanosine enhances glutamate uptake in brain cortical slices at normal and excitotoxic conditions. Cell Mol Neurobiol 22:353-363
87. Galmarini CM, Mackey JR, Dumontet C (2002) Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3:415-424
88. Garakani A, Mathew SJ, Charney DS (2006) Neurobiology of anxiety disorders and implications for treatment. Mt Sinai J Med 73:941-949
89. Geiger JD, Nagy JI (1986) Distribution of adenosine deaminase activity in rat brain and spinal cord. J Neurosci 6:2707-2714
90. Gerevich Z, Wirkner K, Illes P (2002) Adenosine A2A receptors inhibit the N-methyl-D-aspartate component of excitatory synaptic currents in rat striatal neurons. Eur J Pharmacol 451:161-164
91. Gimenez-Llort L, Fernandez-Teruel A, Escorihuela RM, Fredholm BB, Tobena A, Pekny M, Johansson B (2002) Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur J Neurosci 16:547-550
92. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT (2002) BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105:1348-1353
93. Gracia E, Cortés A, Meana JJ, García-Sevilla J, Herhs fi eld MS, Canela EI, Mallol J, Lluís C, Franco R, Casadó V (2008) Human adenosine deaminase as an allosteric modulator of human A(1) adenosine receptor: Abolishment of negative cooperativity for [H](R)-pia binding to the caudate nucleus. J Neurochem 107:161-170
94. Grif fi th GA, Jarvis SM (1996) Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1286:153-181
95. Guillén-Gómez E, Calbet M, Casado J, de Lecea L, Soriano E, Pastor-Anglada M, Burgaya F (2004) Distribution of CNT2 and ENT1 transcripts in rat brain: selective decrease of CNT2 mRNA in the cerebral cortex of sleep-deprived rats. J Neurochem 90:883-893
96. Hagberg H, Andersson P, Lacarewicz J, Jacobson I, Butcher S, Sandberg M (1987) Extracellular adenosine, inosine, hypoxanthine, and xanthine in relation to tissue nucleotides and purines in rat striatum during transient ischemia. J Neurochem 49:227-231
97. Hamilton SP, Slager SL, De Leon AB, Heiman GA, Klein DF, Hodge SE, Weissman MM, Fyer AJ, Knowles JA (2004) Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. Neuropsychopharmacology 29:558-565
98. Hanley SP, Hampton JR (1983) Ventricular arrhythmias associated with lido fl azine: side-effects observed in a randomized trial. Eur Heart J 4:889-893
99. Harper DG, Stopa EG, Kuo-Leblanc V, McKee AC, Asayama K, Volicer L, Kowall N, Satlin A (2008) Dorsomedial SCN neuronal subpopulations subserve different functions in human dementia. Brain 131:1609-1617
100. Harris MK, Shneyder N, Borazanci A, Korniychuk E, Kelley RE, Minagar A (2009) Movement disorders. Med Clin North Am 93:371-388
101. Haskó G, Sitkovsky MV, Szabó C (2004) Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci 25:152-157
102. Haskó G, Pacher P, Vizi ES, Illes P (2005) Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci 26:511-516
103. Hauser SL, Oksenberg JR (2006) The neurobiology of multiple sclerosis: genes, in fl ammation, and neurodegeneration. Neuron 52:61-76
104. Hauser RA, Hubble JP, Truong DD (2003) Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61:286-287
105. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M, Huyck S, Wolski K (2011) Preladenant in patients with Parkinson's disease and motor fl uctuations: A phase 2, doubleblind, randomised trial. Lancet Neurol 10:221-229
106. Headrick JP, Peart JN, Reichelt ME, Haseler LJ (2011) Adenosine and its receptors in the heart: regulation, retaliation and adaptation. Biochim Biophys Acta 1808:1413-1428
107. Heinricher MM, Tavares I, Leith JL, Lumb BM (2009) Descending control of nociception: speci fi city, recruitment and plasticity. Brain Res Rev 60:214-225
108. Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B, Mahmarian JJ (2005) Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol 46:2076-2078
109. Hodgson RA, Bedard PJ, Varty GB, Kazdoba TM, Di Paolo T, Grzelak ME, Pond AJ, Hadjtahar A, Belanger N, Gregoire L, Dare A, Neustadt BR, Stamford AW, Hunter JC (2010) Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders. Exp Neurol 225:384-390
110. Holguin S, Martinez J, Chow C, Wurtman R (2008) Dietary uridine enhances the improvement in learning and memory produced by administering DHA to gerbils. FASEB J 22:3938-3946
111. Honda K, Komoda Y, Nishida S, Nagasaki H, Higashi A, Uchizono K, Inoue S (1984) Uridine as an active component of sleep-promoting substance: its effects on nocturnal sleep in rats. Neurosci Res 1:243-252
112. Honda K, Okano Y, Komoda Y, Inoue S (1985) Sleep-promoting effects of intraperitoneally administered uridine in unrestrained rats. Neurosci Lett 62:137-141
113. Huang ZL, Urade Y, Hayaishi O (2011) The role of adenosine in the regulation of sleep. Curr Top Med Chem 11:1047-1057
114. Inoue S (1986) Sleep and sleep substances. Brain Dev 8:469-473
115. Ipata PL, Camici M, Micheli V, Tozzi MG (2011) Metabolic network of nucleosides in the brain. Curr Top Med Chem 11:909-922
116. Jacobson KA (1998) Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci 19:184-191
117. Jacobson KA, Gao ZG (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5:247-264
118. Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF (2009) Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism Relat Disord 15:406-413
119. Jennings LL, Hao C, Cabrita MA, Vickers MF, Baldwin SA, Young J, Cass CE (2001) Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system. Neuropharmacology 40:722-731
120. Jin S, Fredholm BB (1997) Adenosine A2A receptor stimulation increases release of acetylcholine from rat hippocampus but not striatum, and does not affect catecholamine release. Naunyn Schmiedeberg's Arch Pharmacol 355:48-56
121. Johansson B, Halldner L, Dunwiddie TV, Masino SA, Poelchen W, Gimenez-Llort L, Escorihuela RM, Fernandez-Teruel A, Wiesenfeld-Hallin Z, Xu XJ, Hårdemark A, Betsholtz C, Herlenius E, Fredholm BB (2001) Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci USA 98:9407-9412
122. Jurkowitz MS, Litsky ML, Browning MJ, Hohl CM (1998) Adenosine, inosine, and guanosine protect glial cells during glucose deprivation and mitochondrial inhibition: correlation between protection and ATP preservation. J Neurochem 71:535-548
123. Kaiser SM, Quinn RJ (1999) Adenosine receptors as potential therapeutic targets. Drug Discov Today 4:542-551
124. Kalia M (2005) Neurobiological basis of depression: An update. Metabolism 54:24-27
125. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P (1998) Adenosine A2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43:507-513
126. Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P (2000) Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTPtreated monkeys. Exp Neurol 162:321-327
127. Kékesi KA, Kovács Z, Szilágyi N, Bobest M, Szikra T, Dobolyi Á, Juhász G, Palkovits M (2006) Concentration of nucleosides and related compounds in cerebral and cerebellar cortical areas and white matter of the human brain. Cell Mol Neurobiol 26:831-842
128. Kimura T, Ho IK, Yamamoto I (2001) Uridine receptor: discovery and its involvement in sleep mechanism. Sleep 24:251-260
129. King AE, Ackley MA, Cass CE, Young JD, Baldwin SA (2006) Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci 27:416-425
130. Kirmse K, Dvorzhak A, Grantyn R, Kirischuk S (2008) Developmental downregulation of excitatory GABAergic transmission in neocortical layer I via presynaptic adenosine A(1) receptors. Cereb Cortex 18:424-432
131. Kitagawa M, Houzen H, Tashiro K (2007) Effects of caffeine on the freezing of gait in Parkinson's disease. Mov Disord 22:710-712
132. Kittner B, Rossner M, Rother M (1997) Clinical trials in dementia with propentofylline. Ann N Y Acad Sci 826:307-316
133. Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW (1991) Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. Biol Psychiatry 30:973-984
134. Knapp CM, Foye MM, Cottam N, Ciraulo DA, Kornetsky C (2001) Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration. Pharmacol Biochem Behav 68:797-803
135. Kovács Z, Dobolyi A (2011) Functions and metabolism of brain nucleosides and their metabolites. Curr Top Med Chem 11:907-908
136. Kovács Z, Dobolyi Á, Szikra T, Palkovits M, Juhász G (1998) Uneven regional distribution of nucleotide metabolism in human brain. Neurobiology (Bp) 6:315-321
137. Kovács Z, Kékesi KA, Bobest M, Török T, Szilágyi N, Szikra T, Szepesi Z, Nyilas R, Dobolyi Á, Palkovits M, Juhász G (2005) Post mortem degradation of nucleosides in the brain: comparison of human and rat brains for estimation of in vivo concentration of nucleosides. J Neurosci Methods 148:88-93
138. Kovács Z, Dobolyi A, Juhász G, Kékesi AK (2010a) Nucleoside map of the human central nervous system. Neurochem Res 35:452-464
139. Kovács Z, Juhász G, Dobolyi A, Bobest M, Papp V, Takáts L, Kékesi KA (2010b) Gender-and age-dependent changes in nucleoside levels in the cerebral cortex and white matter of the human brain. Brain Res Bull 81:579-584
140. Kovács Z, Juhász G, Palkovits M, Dobolyi A, Kékesi KA (2011) Area, age and gender dependence of the nucleoside system in the brain: A review of current literature. Curr Top Med Chem 11:1012-1033
141. Kowaluk EA, Jarvis MF (2000) Therapeutic potential of adenosine kinase inhibitors. Expert Opin Investig Drugs 9:551-564
142. Lajtha A, Sershen H (2010) Heterogeneity of reward mechanisms. Neurochem Res 35:851-867
143. Lam P, Hong CJ, Tsai SJ (2005) Association study of A2a adenosine receptor genetic polymorphism in panic disorder. Neurosci Lett 378:98-101
144. Lara DR, Dall'Igna OP, Ghisol fi ES, Brunstein MG (2006) Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry 30:617-629
145. Latini S, Pedata F (2001) Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem 79:463-484
146. Ledent C, Vaugeois JM, Schiffmann SN, Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ, Costentin J, Heath JK, Vassart G, Parmentier M (1997) Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388:674-678
147. Lehman NL (2002) Future potential of thymidylate synthase inhibitors in cancer therapy. Expert Opin Investig Drugs 11:1775-1787
148. Leist TP, Weissert R (2011) Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol 34:28-35
149. Li RW, Tse CM, Man RY, Vanhoutte PM, Leung GP (2007) Inhibition of human equilibrative nucleoside transporters by dihydropyridine-type calcium channel antagonists. Eur J Pharmacol 568:75-82
150. Lima FO, Souza GR, Verri WA Jr, Parada CA, Ferreira SH, Cunha FQ, Cunha TM (2010) Direct blockade of in fl ammatory hypernociception by peripheral A1 adenosine receptors: involvement of the NO/cGMP/PKG/KATP signaling pathway. Pain 151:506-515
151. Linden J, Rosin DL (2006) Purinergic systems. In: Siegel G, Albers RW, Brady S, Price D (eds) Basic neurochemistry: molecular, cellular and medical aspects, 7th edn. Elsevier, Academic Press Inc., New York, USA, pp 303-316
152. Linker RA, Kieseier BC, Gold R (2008) Identi fi cation and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 29:558-565
153. Litsky ML, Hohl CM, Lucas JH, Jurkowitz MS (1999) Inosine and guanosine preserve neuronal and glial cell viability in mouse spinal cord cultures during chemical hypoxia. Brain Res 821:426-432
154. Liu XQ, Sheng R, Qin ZH (2009) The neuroprotective mechanism of brain ischemic preconditioning. Acta Pharmacol Sin 30:1071-1080
155. Lopes LV, Sebastiao AM, Ribeiro JA (2011) Adenosine and related drugs in brain diseases: present and future in clinical trials. Curr Top Med Chem 11:1087-1101
156. Lucas PB, Pickar D, Kelsoe J, Rapaport M, Pato C, Hommer D (1990) Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry 28:35-40
157. Luthin DR, Linden J (1995) Comparison of A 4 and A 2A binding sites in striatum and COS cells transfected with adenosine A 2A receptors. J Pharmacol Exp Ther 272:511-518
158. Mangravite LM, Badagnani I, Giacomini KM (2003) Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. Eur J Pharmacol 479:269-281
159. Markowitz CE, Spitsin S, Zimmerman V, Jacobs D, Udupa JK, Hooper DC, Koprowski H (2009) The treatment of multiple sclerosis with inosine. J Altern Complement Med 15:619-625
160. Marro PJ, Mishra OP, Delivoria-Papadopoulos M (2006) Effect of allopurinol on brain adenosine levels during hypoxia in newborn piglets. Brain Res 1073-1074:444-450
161. Martini C, Daniele S, Picchetti M, Panighini A, Carlini M, Trincavelli ML, Cesari D, Da Pozzo E, Golia F, Dell'Osso L (2011) A(2A) adenosine receptor binding parameters in platelets from patients affected by pathological gambling. Neuropsychobiology 63:154-159
162. McGaraughty S, Cowart M, Jarvis MF, Berman RF (2005) Anticonvulsant and antinociceptive actions of novel adenosine kinase inhibitors. Curr Top Med Chem 5:43-58
163. Melani A, De Micheli E, Pinna G, Al fi eri A, Corte LD, Pedata F (2003) Adenosine extracellular levels in human brain gliomas: An intraoperative microdialysis study. Neurosci Lett 346:93-96
164. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA, Borea PA (2003) A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther 100:31-48
165. Meyer PT, Elmenhorst D, Boy C, Winz O, Matusch A, Zilles K, Bauer A (2007) Effect of aging on cerebral A 1 adenosine receptors: A [18 F]CPFPX PET study in humans. Neurobiol Aging 28:1914-1924
166. Mielke R, Moller HJ, Erkinjuntti T, Rosenkranz B, Rother M, Kittner B (1998) Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials. Alzheimer Dis Assoc Disord 12(Suppl 2):S29-S35
167. Moreau JL, Huber G (1999) Central adenosine A 2A recetors: An overview. Brain Res Rev 31:65-82
168. Müller CE (2003) Medicinal chemistry of adenosine A3 receptor ligands. Curr Top Med Chem 3:445-462
169. Myers CS, Fisher H, Wagner GC (1994) Uridine potentiates haloperidol's disruption of conditioned avoidance responding. Brain Res 651:194-198
170. Nabhan C, Gartenhaus RB, Tallman MS (2004) Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk Res 28:429-442
171. Nagata H, Mimori Y, Nakamura S, Kameyama M (1984) Regional and subcellular distribution in mammalian brain of the enzymes producing adenosine. J Neurochem 42:1001-1007
172. Noji T, Karasawa A, Kusaka H (2004) Adenosine uptake inhibitors. Eur J Pharmacol 495:1-16
173. Norstrand IF, Glantz MD (1980) Topographical distribution of purine nucleoside phosphorylase in the human neuraxis. Enzyme 25:118-122
174. Norstrand IF, Siverls VC, Libbin RM (1984) Regional distribution of adenosine deaminase in the human neuraxis. Enzyme 32:20-25
175. O'Regan M (2005) Adenosine and the regulation of cerebral blood fl ow. Neurol Res 27:175-181
176. Öngür D, Drevets WC, Price JL (1998) Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 95:13290-13295
177. Parkinson FE, Damaraju VL, Graham K, Yao SYM, Baldwin SA, Cass CE, Young JD (2011) Molecular biology of nucleoside transporters and their distributions and functions in the brain. Curr Top Med Chem 11:948-972
178. Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larráyoz I, Martinez-Picado J, Casado JF (2005) Cell entry and export of nucleoside analogues. Virus Res 107:151-164
179. Paul T, Pfammatter JP (1997) Adenosine: An effective and safe antiarrhythmic drug in pediatrics. Pediatr Cardiol 18:118-126
180. Pearce L, Ghosh J, Counsell A, Serracino-Inglott F (2008) Cilostazol and peripheral arterial disease. Expert Opin Pharmacother 9:2683-2690
181. Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR (2001) Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun 280:951-959
182. Peskind ER (1996) Neurobiology of Alzheimer's disease. J Clin Psychiatry 57(Suppl 14):5-8
183. Peterman C, Sanoski CA (2005) Tecadenoson: A novel, selective A1 adenosine receptor agonist. Cardiol Rev 13:315-321
184. Pettifer KM, Kleywegt S, Bau CJ, Ramsbottom JD, Vertes E, Ciccarelli R, Caciagli F, Werstiuk ES, Rathbone MP (2004) Guanosine protects SH-SY5Y cells against beta-amyloid-induced apoptosis. Neuroreport 15:833-836
185. Phillips E, Newsholme EA (1979) Maximum activities, properties and distribution of 5'-nucleotidase, adenosine kinase and adenosine deaminase in rat and human brain. J Neurochem 33:553-558
186. Piccoli F, Camarda R, Bonavita V (1971) The brain nucleotide pattern of the rat after injection of uracil, uridine and uridine phosphate. Acta Neurol (Napoli) 26:109-117
187. Pinna A (2009) Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. Expert Opin Investig Drugs 18:1619-1631
188. Podgorska M, Kocbuch K, Pawelczyk T (2005) Recent advences in studies on biochemical and structural properties of equilibrative and concentrative nucleoside transporters. Acta Biochim Pol 52:749-758
189. Popoli P, Blum D, Martine A, Ledent C, Ceruti S, Abbracchio MP (2007) Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Prog Neurobiol 81:331-348
190. Porkka-Heiskanen T, Kalinchuk AV (2011) Adenosine, energy metabolism and sleep homeostasis. Sleep Med Rev 15:123-135
191. Radulovacki M (1985) Role of adenosine in sleep in rats. Rev Clin Basic Pharm 5:327-339
192. Rando RF, Nguyen-Ba N (2000) Development of novel nucleoside analogues for use against drug rersisitant strains of HIV-1. Drug Discov Today 5:465-476
193. Ribeiro JA, Sebastiao AM, de Mendonca A (2003) Adenosine receptors in the nervous system: pathophysiological implications. Prog Neurobiol 68:377-392
194. Ritchie K, Carriere I, de Mendonca A, Portet F, Dartigues JF, Rouaud O, Barberger-Gateau P, Ancelin ML (2007) The neuroprotective effects of caffeine: A prospective population study (the Three City Study). Neurology 69:536-545
195. Ritzel MWL, Ng AML, Yao SYM, Graham K, Loewen SK, Smith KM, Ritzel RG, Mowles DA, Carpenter P, Chen XZ, Karpinski E, Hyde RJ, Baldwin SA, Cass CE, Young JD (2001) Molecular identi fi cation and characterization of novel human and mouse concentrative Na +-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 276:2914-2927
196. Robak T, Korycka A, Lech-Maranda E, Robak P (2009) Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases. Molecules 14:1183-1226
197. Roberts CA (1973) Anticonvulsant effects of uridine: comparative analysis of metrazol and penicillin induced foci. Brain Res 55:291-308
198. Roberts CA, Kreisman NR, Waltman M (1974) Uridine anticonvulsant effects: selective control of nucleoside incorporation in experimental epilepsy. Epilepsia 15:479-500
199. Roesler R, Vianna MR, Lara DR, Izquierdo I, Schmidt AP, Souza DO (2000) Guanosine impairs inhibitory avoidance performance in rats. Neuroreport 11:2537-2540
200. Roos RA, Bots GT, Hermans J (1985) Neuronal nuclear membrane indentation and astrocyte/neuron ratio in Huntington's disease. A quantitative electron microscopic study. J Hirnforsch 26:689-693
201. Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT (2006) Neurobiology of schizophrenia. Neuron 52:139-153
202. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB (1992) Adenosine and brain ischemia. Cerebrovasc Brain Metab Rev 4:346-369
203. Saper CB (2006) Staying awake for dinner: hypothalamic integration of sleep, feeding, and circadian rhythms. Prog Brain Res 153:243-252
204. Saute JA, da Silveira LE, Soares FA, Martini LH, Souza DO, Ganzella M (2006) Amnesic effect of GMP depends on its conversion to guanosine. Neurobiol Learn Mem 85:206-212
205. Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferré S (2007) Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol 83:277-292
206. Schmidt AP, Lara DR, de Faria Maraschin J, da Silveira Perla A, Souza DO (2000) Guanosine and GMP prevent seizures induced by quinolinic acid in mice. Brain Res 864:40-43
207. Schmidt AP, Lara DR, Souza DO (2007) Proposal of a guanine-based purinergic system in the mammalian central nervous system. Pharmacol Therapeut 116:401-416
208. Schmidt AP, Böhmer AE, Schallenberger C, Antunes C, Pereira MS, Leke R, Wofchuk ST, Elisabetsky E, Souza DO (2009) Spinal mechanisms of antinociceptive action caused by guanosine in mice. Eur J Pharmacol 613:46-53
209. Schulte G, Fredholm BB (2003) Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal 15:813-827
210. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M (2006) Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 29:647-654
211. Shen H, Chen GJ, Harvey BK, Bickford PC, Wang Y (2005) Inosine reduces ischemic brain injury in rats. Stroke 36:654-659
212. Sperlágh B, Vizi ES (2011) The role of extracellular adenosine in chemical neurotransmission in the hippocampus and Basal Ganglia: pharmacological and clinical aspects. Curr Top Med Chem 11:1034-1046
213. Spiers PA, Myers D, Hochanadel GS, Lieberman HR, Wurtman RJ (1996) Citicoline improves verbal memory in aging. Arch Neurol 53:441-448
214. Stone TW (2002) Purines and neuroprotection. Adv Exp Med Biol 513:249-280
215. Svenningsson P, Hall H, Sedvall G, Fredholm BB (1997) Distribution of adenosine receptors in the postmortem human brain: An extended autoradiographic study. Synapse 27:322-335
216. Teather LA, Wurtman RJ (2003) Dietary cytidine (5')-diphosphocholine supplementation protects against development of memory de fi cits in aging rats. Prog Neuropsychopharmacol Biol Psychiatry 27:711-717
217. Teather LA, Wurtman RJ (2005) Dietary CDP-choline supplementation prevents memory impairment caused by impoverished environmental conditions in rats. Learn Mem 12:39-43
218. Teather LA, Wurtman RJ (2006) Chronic administration of UMP ameliorates the impairment of hippocampal-dependent memory in impoverished rats. J Nutr 136:2834-2837
219. Togha M, Akhondzadeh S, Motamedi M, Ahmadi B, Razeghi S (2007) Allopurinol as adjunctive therapy in intractable epilepsy: A double-blind and placebo-controlled trial. Arch Med Res 38:313-316
220. Tomassoni D, Lanari A, Silvestrelli G, Traini E, Amenta F (2008) Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin Exp Hypertens 30:744-766
221. Tort AB, Mantese CE, dos Anjos GM, Dietrich MO, Dall'Igna OP, Souza DO, Lara DR (2004) Guanosine selectively inhibits locomotor stimulation induced by the NMDA antagonist dizocilpine. Behav Brain Res 154:417-422
222. Traut TW (1994) Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 140:1-22
223. Traversa U, Bombi G, Di Iorio P, Ciccarelli R, Werstiuk ES, Rathbone MP (2002) Speci fi c [(3) H]-guanosine binding sites in rat brain membranes. Br J Pharmacol 135:969-976
224. Tsai SJ, Hong CJ, Hou SJ, Yen FC (2006) Association study of adenosine A2a receptor (1976 C > T) genetic polymorphism and mood disorders and age of onset. Psychiatr Genet 16:185
225. Tucker AL, Linden J (1993) Cloned receptors and cardiovascular responses to adenosine. Cardiovasc Res 27:62-67
226. Van der Beek EM, Kamphuis P (2008) The potential role of nutritional components in the management of Alzheimer's Disease. Eur J Pharmacol 585:197-207
227. Van Rompay AR, Johansson M, Karlsson A (2003) Substrate speci fi city and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases. Pharmacol Therapeut 100:119-139
228. Varani K, Merighi S, Gessi S, Klotz KN, Leung E, Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Borea PA (2000) [(3)H]MRE 3008 F20: A novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. Mol Pharmacol 57:968-975
229. Vinadé ER, Schmidt AP, Frizzo ME, Izquierdo I, Elisabetsky E, Souza DO (2003) Chronically administered guanosine is anticonvulsant, amnesic and anxiolytic in mice. Brain Res 977:97-102
230. Volonté C, D'Ambrosi N (2009) Membrane compartments and purinergic signalling: The purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. FEBS J 276:318-329
231. Volpini R, Costanzi S, Vittori S, Cristalli G, Klotz KN (2003) Medicinal chemistry and pharmacology of A2B adenosine receptors. Curr Top Med Chem 3:427-443
232. Von Lubitz DK (2001) Adenosine in the treatment of stroke: yes, maybe, or absolutely not? Expert Opin Investig Drugs 10:619-632
233. Wardas J (2002) Neuroprotective role of adenosine in the CNS. Pol J Pharmacol 54:313-326
234. Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC (2010) Identi fi cation of targets and new developments in the treatment of multiple sclerosis-focus on cladribine. Drug Des Devel Ther 4:117-126
235. Weber G, Prajda N (1994) Targeted and non-targeted actions of anti-cancer drugs. Adv Enzyme Regul 34:71-89
236. Weber G, Ichikawa S, Nagai M, Natsumeda Y (1990) Azidothymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-fl uorouracil in rat hepatoma and human colon cancer cells. Cancer Commun 2:129-133
237. Weerts EM, Grif fi ths RR (2003) The adenosine receptor antagonist CGS15943 reinstates cocaineseeking behavior and maintains self-administration in baboons. Psychopharmacology (Berl) 168:155-163
238. Weyrich AS, Skalabrin EJ, Kraiss LW (2009) Targeting the in fl ammatory response in secondary stroke prevention: A role for combining aspirin and extended-release dipyridamole. Am J Ther 16:164-170
239. Wiesner JB, Ugarkar BG, Castellino AJ, Barankiewicz J, Dumas DP, Gruber HE, Foster AC, Erion MD (1999) Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy. J Pharmacol Exp Ther 289:1669-1677
240. Willis RC, Carson DA, Seegmiller JE (1978) Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. Proc Natl Acad Sci USA 75:3042-3044
241. Willuhn I, Wanat MJ, Clark JJ, Phillips PE (2010) Dopamine signaling in the nucleus accumbens of animals self-administering drugs of abuse. Curr Top Behav Neurosci 3:29-71
242. Wurtman RJ, Regan M, Ulus I, Yu L (2000) Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochem Pharmacol 60:989-992
243. Wurtman RJ, Cansev M, Sakamoto T, Ulus IH (2009) Use of phosphatide precursors to promote synaptogenesis. Annu Rev Nutr 29:59-87
244. Xu K, Bastia E, Schwarzschild M (2005) Therapautic potential of adenosine A 2A receptor antagonists in Parkinson's disease. Pharmacol Ther 105:267-310
245. Yegutkin GG (2008) Nucleotide-and nucleoside converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta 1783:673-694
246. Zapor MJ, Cozza KL, Wynn GH, Wortmann GW, Armstrong SC (2004) Antiretrovirals, part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). Psychosomatics 45:524-535
247. Zaza A (2002) CVT-510 (CV Therapeutics). Curr Opin Investig Drugs 3:96-100
248. Zhao Q, Marolewski A, Rusche JR, Holmes GL (2006) Effects of uridine in models of epileptogenesis and seizures. Epilepsy Res 70:73-82
249. Zhao Q, Shatskikh T, Marolewski A, Rusche JR, Holmes GL (2008) Effects of uridine on kindling. Epilepsy Behav 13:47-51
250. Zimmermann H (1996) Biochemistry, localization and functional roles of ecto-nucleotidases in the nervous system. Prog Neurobiol 49:589-618
251. Zoref-Shani E, Bromberg Y, Lilling G, Gozes I, Brosh S, Sidi Y, Sperling O (1995) Developmental changes in purine nucleotide metabolism in cultured rat astroglia. Int J Dev Neurosci 13:887-896